Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00363376 · ClinicalTrials.gov registry record · Phase 3
A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain
A Phase 3 study, sponsored by Lindner Center of HOPE.
- Completed
- Registry status
- Phase 3
- Development phase
- 42
- Enrollment target
NCT00363376 is a Phase 3 study that has completed, run by Lindner Center of HOPE. The registered enrollment target is 42 participants.
The verdict
NCT00363376, a Phase 3 study, has completed, sponsored by Lindner Center of HOPE.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 42 participants
- Enrollment target
Study Summary
The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.
Interventions
- DRUG Zonisamide
- DRUG olanzapine
- DRUG Sugar Pill (placebo)
- DRUG zonisamide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2008-01 |
| Est. Completion | 2011-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00363376
The ClinicalTrials.gov registry entry for NCT00363376 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lindner Center of HOPE, which has 23 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Zonisamide is the first listed.
NCT00363376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00363376 about?
NCT00363376 is a clinical study titled "A Study of Zonisamide to Prevent Olanzapine-Associated Weight Gain". The specific aim of this study is to evaluate the efficacy, tolerability, and safety of zonisamide therapy in the prevention of weight gain associated with olanzapine treatment for psychotic or bipolar disorders.
What is the current status of trial NCT00363376?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 42 participants. The study started on 2008-01. Estimated completion is 2011-02.
What interventions are being tested in trial NCT00363376?
The interventions under investigation include: Zonisamide (DRUG), olanzapine (DRUG), Sugar Pill (placebo) (DRUG), zonisamide (DRUG).
Who is sponsoring clinical trial NCT00363376?
This trial is sponsored by Lindner Center of HOPE, which has 23 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.